Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Oct 21, 2024

BUY
$18.45 - $27.14 $470,641 - $692,314
25,509 New
25,509 $481,000
Q1 2023

May 03, 2023

SELL
$18.45 - $27.14 $140,386 - $206,508
-7,609 Reduced 22.98%
25,509 $481,000
Q4 2022

Feb 13, 2023

BUY
$20.18 - $33.33 $453,404 - $748,858
22,468 Added 210.97%
33,118 $816,000
Q3 2022

Nov 07, 2022

SELL
$11.58 - $24.73 $238,698 - $509,759
-20,613 Reduced 65.93%
10,650 $191,000
Q2 2022

Aug 09, 2022

BUY
$8.52 - $25.26 $72,104 - $213,775
8,463 Added 37.12%
31,263 $355,000
Q1 2022

May 12, 2022

BUY
$19.89 - $43.18 $153,153 - $332,486
7,700 Added 50.99%
22,800 $508,000
Q4 2021

Feb 10, 2022

BUY
$26.75 - $46.02 $403,925 - $694,902
15,100 New
15,100 $659,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $565M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.